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INTRODUCTION 
Mycobacterium Tuberculosis (TB) is a bacterium that is spread by a person inhaling 
the bacteria via aerosol droplets during coughing or sneezing by an individual with 
infectious TB (NICE 2006). Over the past century the United Kingdom (UK) has 
made significant progress in combating TB. This has been achieved through 
improved healthcare and better preventative measures. The epidemiology of TB is 
changing and it is now identified as a new threat that needs concerted action to deal 
with it (Department of Health 2004). 
An important component of TB control in a country with a low prevalence rate of TB 
such as the UK, is to identify and treat persons with latent TB infection and therefore 
prevent the development of active disease (O’Brien 2003). Patient concordance with 
this treatment is essential as non-compliance may lead to an increase in drug 
resistance especially to Rifampicin (O’Brien 2003). One of the major barriers to 
concordance with treatment, as identified by O’Brien (2003), is the requirement of a 
well person to take the medication over a long period of time with marginal personal 
benefit. Many studies and surveys indicate that non adherence to latent tuberculosis 
treatment is considerable. In the United States non-adherence to self administered 
tuberculosis medication varies from 82% in hard to reach groups to 11% in the 
general population (McDonnell, Turner and Weaver 2001). 
The British National Formulary (BNF 2010) and the National Institute for Clinical 
Excellence (NICE 2006) recommends two treatment regimens for latent TB infection 
with either six months of Isoniazid or a shorter three month regimen using a 
combined treatment with Isoniazid and Rifampicin dependent on age or HIV status. 
Traditionally most patients received six months of Isoniazid but there is now a trend 
to use the shorter 3 month regimen guided by clinician and patient preference 
(Rennie et al 2007). Research from outside the UK has demonstrated that shorter 
treatment regimens for latent tuberculosis have significantly improved medication 
concordance rates. (Spyridis et al 2007, McNeill et al 2003, Lobato et al 2005, 
Menzies et al 2004 and Lardizabal et al 2006).  
AIMS AND AUDIT OBJECTIVES 
The aim of the project was to determine whether concordance with TB treatment is 
affected by the length of the regimen in patients with latent TB infection in the UK. 
Audit objectives were to: 
1.     Determine the completion rates for the treatment of latent tuberculosis 
infection over a 3 year period.  
2.     Compare treatment completion rates between the 6 month and 3 month 
regimens  
3.     Establish the prevalence of side effects in the 3 and 6 month treatment 
regimen. 
4.     Identify whether demographic factors have an impact on treatment 
completion. 
AUDIT STANDARDS 
A retrospective clinical audit was conducted to address the aims and objectives. 
1. All patients commenced on treatment for latent TB infection should complete their 
prescribed course of medication with a 100% desired performance level with the 
exceptions of death or life threatening side effects. 
2. All patients identified as suitable for latent TB treatment would be commenced on 
either Isoniazid monotherapy or a combined treatment of Rifampicin and Isoniazid. 
SAMPLE  
Clinical records which included patient’s records and computerised data were 
searched to identify patients who met the following criteria.  
1.   Patients with clinically identified latent TB infection between 1st January 2006 
and 31st December 2008 
2.   Patients commenced on either a monotherapy of Isoniazid or combined 
treatment of Rifampicin and Isoniazid between 1st January 2006 and 31st 
December 2008 
A total of 57 patients fulfilled the criteria for inclusion in the audit. 
RESULTS 
Characteristics of the sample 
Ages ranged from 16-80 years with a mean age of 33 years. Thirty eight patients 
(66.7%) were born outside of UK. In non-UK born patients, ethnic origin was split into 
TB notification format which identified the largest patient population as Black African 
33.3% (19), Pakistani 19.3% (11), Chinese 3.5% (2) and other 12.3% (7).  
Referral to the service during the three year period was split into six main areas with 
the highest number of patients being asylum seekers referred by local GP practice 
(Table 1).  
Table 1. Patient numbers by method of referral to the TB service 
Source of referral No. of patients 
(%) 
Asylum seekers identified through local GP practice 21 (36.8%) 
Identification through contact tracing 12 (21.1%) 
Identification through  pre-treatment assessment (for drugs such as 
anti-TNF therapy) 
9 (15.8%) 
Identification through new immigrant screening via port health forms 7 (12.3%) 
Occupational health pre-screening 6 (10.5%) 
Characteristics of treatment and treatment regimen 
Forty three patients (75.4%) were commenced on the combined treatment of 
Rifampicin and Isoniazid for 3 months compared with 24.6% (14) patients who were 
commenced on Isoniazid monotherapy for 6 months (Table 2). Patient records were 
examined to identify whether the regimen was changed during treatment from the 3 
to 6 month or 6 to 3 month regimen. Thirty five (81.4%) patients on the 3 month 
regimen remained unchanged during treatment, while the rest of patients later 
changed treatment to the 6 month regimen. It was reported that this change was due 
to side effects, pregnancy or drug interaction. None of the patients on the 6 month 
regimen changed to the three month regimen during treatment (Table 3).  
 
Table 2. Percentage of patients on each regime, split by gender 
0.0% 
10.0% 
20.0% 
30.0% 
40.0% 
50.0% 
60.0% 
70.0% 
3 months INR 41.9% 58.1% 
6 months IN 35.7% 64.3% 
Male Female 
Side effects of treatment 
Side effects or adverse reactions were identified from the patient’s notes and 
measured using known side effects identified in the BNF ( 2010). Side effects of 
treatment were noted with both regimens, with a higher proportion of patients in the 
three month regimen (46.5%) reporting side effects than on the six month treatment 
regimen (28.5%). The most commonly reported side effects were nausea (10%), 
urticaria (10%) and rash (10%). 
When the presence of side effects was examined by age, the younger age group 
had fewer side effects (16 – 24 yrs) of which 26% reported one or more side effects. 
This percentage rose to 50% in the 25 – 34; 35 – 44 and 45 – 45 year age groups 
and but interestingly dropped to 44% in the over 55 year old group. There were no 
differences in the frequency of side effects based on ethnicity.  
Treatment completion and concordance  
Overall treatment completion (both regimens) was seen in 40 patients (70.2%). Four 
(7%) patients did not complete their treatment either out of choice (2), abnormal liver 
function (1) or not known (1) while 13 were lost to follow up or their treatment 
completion was unknown (22.8%). The results for each treatment regimen are 
shown in table 2. 
Table 3. Completion rates and reasons for non-completion  
   
  
3 month regimen (n= 43) 6 month regimen (n=14) 
Completed treatment 67.4% (29) 78.6% (11) 
Did not complete 
Lost to follow up 
Switched regimen 
7.0% (3) 
25.6% (11) 
18.6% (8) 
7.1%% (1) 
14.3% %(2) 
0.0%(0) 
Review of socio-demographic data revealed more men (78%) than women (65%) 
completed their treatment. Treatment completion was higher in UK born patients 
(79%) compared with non UK born patients (66%).A greater number of non UK born 
patients were lost to follow up 29% (11) compared to UK born patients 11% (2). 
 
 
 
Table 4: Age group and completion of treatment: 
Age Completed Treatment Frequency Percentage 
16 - 34 Yes 
No 
Not know (lost to follow up, side effects) 
28 
2 
12 
49.1% 
3.6% 
21.0% 
35 – 55+ Yes 
No 
Not known 
12 
2 
1 
21.0% 
3.6% 
1.7% 
DISCUSSION 
The aim of this retrospective audit was to determine whether concordance with TB 
treatment is affected by the length of the regimen in patients with latent TB and the 
relationship between side effects or demographics and treatment regimen used.  
The results of this audit indicate that changing from a monotherapy six month 
treatment regimen to a combined therapy three month treatment regimen has not 
improved treatment concordance. In this study, treatment completion rates were 
higher in the single therapy treatment group (78.6%) when compared with the 
combined therapy treatment group (67.4%). This contradicts findings from outside 
the UK where shorter treatment regimens with combined therapy reported  improved 
treatment completion rates than the longer Isoniazid therapy treatment regimen 
(Spyridis et al 2007, McNeill et al 2003, Lobato et al 2005, Menzies et al 2004 and 
Lardizabal et al 2006). 
The reason for this difference is unclear. Current guidelines within the United States 
recommend monotherapy using either Isoniazid for 6 or 9 months or Rifampicin for 4 
months. A combination of Rifampicin and Pyrazinamide is no longer recommended 
for the treatment of latent TB because of the high rate of hepatoxicity (Centre for 
Disease Control 2005). This is not consistent with current recommendations in the 
UK (NICE 2011). 
Seemingly poorer treatment completion in the three-month combined therapy group 
may have been influenced by loss to follow up in this group and may be partly 
explained by differences in the prevalence of side effects. In this study, 46.5% of 
patients (20) in the 3-month combined regimen group experienced side effects 
compared with 28.5% (4) in the 6 month single therapy group. Although only 3 
patients reported side effects as the reason for stopping their treatment, it is 
reasonable to assume that the majority of those lost to follow up were lost due to 
patient decisions to stop treatment or issues out of their control.  
It appeared that the identified non completion rate in both groups was approximately 
7% but 8 patients did change from the 3 month to 6 month regimen which helped 
maintain the overall completion rate of 70.2%. 
The audit identified that 22.8% of the total study population were  lost to follow up 
patients who could not be accounted for, whether they fully completed their 
treatment, partially completed their treatment and if not for what reason and whether 
there were any adverse events in this group. Lost to Follow up rates vary in some 
studies such as Lardizabal et al (2006) who reported a rate of 34.7% in their 9 month 
regimen but only 12.6% in their 4 month regimen, while Kwara et al (2008) reported 
a 35.6% lost to follow up rate with the use of a 9 month treatment regimen. The 
results of this are therefore consistent with existing literature in this respect  
The main concern in this study appears to be the large number of lost to follow up 
patients. We were unaware whether these patients completed their medication and 
the possibility of partial treatment raises the issue of multi-drug resistant TB (MDR-
TB).  
When considering whether the patient was UK born or not, 29% of the non UK study 
population were more likely to be lost to follow up compared to only 11% of the UK 
population. The two main groups identified as lost to follow up were Black African 
26% and ‘Other’ 57% which included patients from the European and  Asian 
continents. Age revealed that the younger age group were more likely to be lost to 
follow up, with 38% of the 16-24 year age group, 23% of the 25-34 year age group 
and 25% of the 35-44 year age group. None of the older age group were lost to 
follow up and appeared to be a more stable study population.   
Dalal et al (2008, pg 101) reported similar data in a lost to follow up specific single 
centre study with 1 in 6 patients lost to follow up. This appears to be a problem in TB 
treatment and can have direct consequences when it comes to preventing MDR-TB 
and the difficulties this would present. Treatment completion in this study is 
encouraging but to eliminate TB further attention needs to be focused on completion 
rates to prevent active infection. 
 
 
 
STUDY LIMITATIONS 
The results of this study may not be applicable to other social groups or populations. 
A considerable number of patients were lost to follow-up were potential side effects 
and completion of treatment are not entirely clear. The 6 month group was 
significantly underrepresented in this study. 
KEY FINDINGS 
1.   Treatment completion is higher in the six month group although the total number 
of   patients in this group was lower than the 3 month group 
2.   The three month group experienced more side effects 
3.   Younger patients experienced more side effects and were more likely to be lost 
to follow up  
4.   There was a substantial lost to follow up rate  
5.   Further studies are required to identify specific demographics of patients lost 
to         follow up and measures to reduce their numbers.                               
CONCLUSION 
Overall, the completion of treatment for latent TB infection has not been affected by 
the introduction of the 3 month treatment regimen in this population with 
concordance actually better in the 6 month regimen. The study has highlighted the 
concern of lost to follow patients. The study demonstrated that patients under 35 
years of age who were non UK born i.e. belonged to either the Black African or 
Pakistani population groups were more likely to be lost to follow up.  This group 
needs to be targeted specifically when treating patients with latent TB infection. 
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